Redeye raises its full-year 2022 forecast but maintains its previous expectations for the years afte...
Redeye comments on the events of the third quarter, including progress with the main candidate Pulmo...
Q3 i korthet Under det tredje kvartalet 2022 uppvisade Physitrack en omsättning om EUR 3,4m (EUR 2,0...
Omsättning och EBITDA i linje med våra estimat Omsättningen uppgick till EUR 22.
Redeye positively views the news that Lifeclean has developed an effective method for removing PFAS ...
I dag offentliggjorde Angler Gaming sin delårsrapport för det tredje kvartalet 2022.
Redeye continues to see a very compelling ling term investment case.
Redeye comments on QleanAir’s Q3 figures, with sales and EBITDA slightly below estimates.
EBIT missed ABGSCe by 80%, mainly on softer sales Expect cons to cut ‘22e EBIT by 27% There is a con...
We lower ’23e EBIT by 4% Negatively affected by hedge prices The share is trading at ~6x P/E on 2023...
Sales and EBIT beat of 45% and 17% We raise estimates on Q3 numbers and eMELT Positive outlook intac...
Redeye states that the quarterly financials were more or less in line with expectations, and we only...
Relais reported Q2 adjusted EBITA of EUR 7.9m, 4% below our estimate.
Redeye ser fortsatt positivt på Irlab efter att ha tagit del av företagets Q3-rapport, som kom in so...
Redeye provides its initial take on Surgical Science’s Q3 2022 report, which came in above our estim...
Redeye provides an update on M.O.B.A. following its strong Q2 2022 report.
Redeye updates on Better Collective ahead of its Q3-results (due 17 November) where we expect solid ...
Redeye retains its positive view of Speqta following a solid Q3 report.
Cibus's Q3 2022 income from property management (IFPM) was above consensus when adjusted for EUR -1.
Redeye takes a positive stance towards Hanza following a solid Q3 report, new ambitious financial ta...
